DDInter1429 DDInter927
Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Perflutren {u} (Compound) resembles {v} (Compound) Sevoflurane
Perflutren {u} (Compound) is included by {v} (Pharmacologic Class) Ultrasound Contrast Activity
Perflutren {u} (Compound) causes {v} (Side Effect) Haemoglobin
Perflutren {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Perflutren {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lactulose
Perflutren {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Perflutren {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Perflutren {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Perflutren (Compound) resembles Sevoflurane (Compound)
Perflutren (Compound) is included by Ultrasound Contrast Activity (Pharmacologic Class)
Perflutren (Compound) causes Haemoglobin (Side Effect)
Perflutren may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Lactulose
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Perflutren may lead to a major life threatening interaction when taken with Cabozantinib
Perflutren may lead to a major life threatening interaction when taken with Anagrelide